Introduction
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis is one of the world's most deadly pathogens, with 1.4 million deaths in 2011 alone. The pathogen is characterized by a sophisticated and complex cell wall architecture. [1] [2] [3] [4] Many of the lipids and glycolipids that make up the Mtb cell wall are believed to be virulence factors that play a key role in host-pathogen interactions and disease pathogenesis. [5] [6] [7] [8] [9] [10] Glycosyl processing enzymes are essential for bacterial cell wall biosynthesis and many of the key components of the cell wall display complex carbohydrates. 11, 12 The critical and diverse biological functions of these glycans in the life-cycle of the mycobacterium are only beginning to be understood. Phenolic glycolipids (PGLs) are a family of bacterial glycolipids with a lipid core similar to dimycocerosates of phthiocerol (DIMs). [13] [14] [15] [16] [17] PGLs contain an aromatic nucleus that is glycosylated by a strain-specific, mono, di, tri or tetrasaccharide (Fig. 1) . The carbohydrate region is composed of the 6-deoxy sugars, L-rhamnose and L-fucose and is usually decorated with a very specific methylation pattern. These glycosylated lipids are important for mycobacterial disease pathogenesis and have been associated with an inhibition of the release of key inflammatory effector molecules by cells of the host's innate immune response. 18, 19 PGL-1 has been isolated from strains of the related mycobacterium, M. leprae, the causative agent of leprosy. The carbohydrate region of PGL-1 binds to the α2LG1, α2LG4 and α2LG5 modules of the peripheral nerve laminin α2 chain and promotes phagocytosis of M. leprae by macrophages and Schwann cells. 20 The carbohydrate region of PGLs is critical to their activity. Despite the acute biological effects of these 
Results and discussion
The p-HBADs play a key role in M. tuberculosis disease pathogenesis and recent studies have suggested that these glycans have potent immunomodulatory activity. Data from Mtb strains defective in the synthesis of p-hydroxybenzoic acid derivatives suggest that p-HBADs influence the release of key inflammatory cytokines by macrophages. 22 It is difficult to derive definitive conclusions regarding the biological roles of specific p-HBADs from studies using Mtb since the bacterium secretes heterogeneous mixtures of glycoconjugates with variable ratios of p-HBADs. It is also challenging to probe the biological role of the unusual methylation pattern displayed on the p-HBADs. In order to directly study the immunomodulatory effects of the p-HBADs in the absence of the parent bacterium, we set out to prepare synthetic samples of p-HBAD-I (both methylated and unmethylated at the 2-OH position) and p-HBAD-II with its native methylation pattern. The immunomodulatory effects of these compounds were tested in vitro using mouse splenocytes and bone marrow derived macrophages. Synthesis of the trisaccharide unit of p-HBAD-II has been described previously. 27, 28 However, our reported strategy for regioselective protection of hydroxyl groups offers an alternative synthetic route with comparable yields to these reported syntheses. Recently, the total synthesis of PGL-tb1 has been reported but this approach also differs considerably from our reported strategy. 29 The synthesis of the PGL mycoside-B and p-HBAD-I have also recently been reported, highlighting the interest in accessing synthetically pure samples of these compounds for biological study. 30 The overall synthetic route to p-HBAD-I is outlined in Scheme 1. The regioselective methylation of the 2-OH position of L-rhamnose required a number of protecting group manipulations and a general protecting group strategy was developed that allowed regioselective access to each hydroxyl groups on rhamnose moiety. Glycosylation with methyl p-hydroxybenzoate was carried out at a late stage in the synthesis. Starting from per-acetylated rhamnose 1, a Lewis acid catalysed glycosylation reaction with ethane thiol furnished thioglycoside donor 2. Thioglycosides are widely used as glycosyl donors in carbohydrate synthesis due to their relative stability and ability to tolerate functional group modifications on the sugar. 31 Removal of the acetate protecting groups under Zemplén conditions followed by regioselective protection of the 2-and 3-OH groups with a cyclic acetal furnished partially protected donor 4. Benzylation of the free 4-OH followed by hydrolysis of the acetal protecting group furnished the diol 6. 32,33 A regioselective hydrolysis of an orthoester was used to access 7. 34 The resulting free 3-OH was protected with a levulinoyl protecting group which was selected to be orthogonal to both the acetyl and benzyl protecting groups. Following deacetylation of the 2-OH to give 9 (this compound was employed as a starting point for the synthesis of p-HBAD-II), the methyl group was introduced in good yield using methyl iodide as the alkylating agent. It was found that using an excess sodium hydride could remove the levulinoyl protecting group quantitatively in a one-pot system to give 10. The free 3-OH was acetylated to give thioglycoside 11 which was employed as a glycosyl donor for the glycosylation reaction with methyl p-hydroxybenzoate to furnish the protected p-HBAD-I 12. Deprotection of 12 in two steps, furnished the fully synthetic p-HBAD-I 14 in a good yield. The synthetic strategy is advantageous in that all of the synthetic steps are high yielding and the key intermediates 9 and 13 could be used directly for the preparation of the more complex oligosaccharide, p-HBAD-II.
The synthesis of the p-HBAD-II trisaccharide was based on the strategy developed for p-HBAD-I. A sequential glycosylation strategy employing two thioglycoside donors was used. The overall synthetic scheme is outlined in Scheme 2. Starting from the levulinoyl protected compound 9, treatment with benzyl bromide and an excess of sodium hydride gave the partially protected glycosyl donor 15. This compound was acetylated at the 3-OH position and then employed in a glycosylation reaction with the acceptor 13 that was prepared previously as part of the p-HBAD-I synthesis. The disaccharide 17 was formed in good yield with complete alpha selectivity (as determined by 1 H-NMR analysis), despite the absence of a participating group at the 2-OH position. The 3-OH position of the terminal rhamnose residue was deprotected and glycosylation with the per-O-methylated fucosyl thioglycoside donor 19 35 furnished the protected trisaccharide 20 in good yield.
Removal of the benzyl protecting groups under palladium-catalysed hydrogenation conditions furnished the fully synthetic p-HBAD-II with the native methylation pattern. In order to probe the role of the methyl group on the 2-OH position of p-HBAD-I, the unmethylated derivative (UM-p-HBAD-I) was also prepared. This unmethylated p-HBAD was previously isolated from a mutant strain of M. tuberculosis taken from a transposon mutant library, and may be an intermediate in the biosynthesis of p-HBADs. 21 The per-acetylated rhamnosyl donor 1 was glycosylated with the methyl p-hydroxybenzoate to furnish 22 which was subsequently deprotected to furnish the fully unmethylated UM-p-HBAD-I 23 (Scheme 3).
Cell studies
Mouse splenocytes and Bone Marrow Derived Macrophages (BMM) were employed for the in vitro studies. Splenocytes comprise a mixed population of white blood cells originating in the spleen that play a key role in immune responses. Here, splenocytes were incubated with the T lymphocyte activating stimulus, anti-CD3e, to promote lymphocyte proliferation and cytokine production. Cells were also incubated with each of the p-HBADs at various concentrations alone or together with anti-CD3e antibody to assess if the molecules could induce, inhibit or modulate cytokine secretion. Cytokine production by splenocytes and macrophages was quantified by enzymelinked immunosorbent assay (ELISA). Flow cytometry was used to examine intracellular cytokines produced by CD4 and CD8 cells and to assess cell proliferation by intracellular fluorescent label carboxyfluorescein diacetate succinimidyl ester (CFSE) incorporation (Fig. 2) . p-HBADs were tested at concentrations of 20 μM, 100 μM and 500 μM for their ability to induce cytokines or to modulate anti-CD3e (0.4 μg mL −1 ) induced cytokine secretion by splenocytes. p-HBAD-I, p-HBAD-II and UM-p-HBAD-I inhibited the secretion of IFN-γ, IL-17 and IL-10 by anti-CD3e-stimulated splenocytes, particularly at a concentration of 500 μM. This reduction was significant at the higher concentration of 500 μM but was still observed at the lower concentrations of the p-HBADs. In the absence of anti-CD3e there was no enhancement in cytokine secretion indicating that the p-HBADs themselves do not have immunostimulatory properties. The effect of p-HBADs on intracellular IFN-y was examined by flow cytometry (Fig. 3) . p-HBAD-I, p-HBAD-II or UM-p-HBAD-I alone did not induce CD4 + T cell proliferation or intracellular IFN-γ production. However, p-HBAD-I, p-HBAD-II and UM-p-HBAD-I suppressed intracellular IFN-γ production by activated CD4 + T cells.
From the above data we can conclude that in the presence of anti-CD3, the three p-HBADs inhibit IFN-γ production but not the proliferation of T h cells. Following from this we can conclude that the p-HBADs examined antagonize the effect of the anti-CD3 stimulus on IFN-γ production but enhance its effect on T h cell proliferation. Thus we can put forth the Scheme 2 Synthetic strategy for the preparation of p-HBAD-II. postulate that p-HBADs inhibit the production of proinflammatory cytokines (due to the knock-on effect of decreased IFN-γ production) but do not adversely affect T h cell proliferation. The p-HBADs appear to have similar effects on both CD3 + CD4 + and CD3 + CD4 − cells. Given the central importance of IFN-γ production in protective immunity to Mtb 36, 37 these results indicate that p-HBADS may help the bacterium evade the antibacterial effects of this key cytokine. Macrophages play a vital role in Mtb pathogenesis and are often the first line of defence in the host response to Mtb infection. Macrophages are also key antigen presenting cells that can induce antigen specific CD4 + T cell responses which have been implicated in protective immunity against TB. 38 In addition, recent studies with Mtb have determined that some cell wall glycolipids can directly inhibit CD4 + T cell activation. [39] [40] [41] [42] The effects of the p-HBADs on macrophages therefore provide a valid in vitro measure of the immunomodulatory effects of p-HBADs in the context of Mtb pathogenesis.
BMM were incubated with irradiated H37Rv in the presence or absence of the p-HBADs, with the compounds added directly to the cell supernatant. The results of the macrophage experiments are presented in Fig. 4 . Cells stimulated with irradiated H37Rv produced the pro-inflammatory cytokines TNF-α, IL-12p40 and IL-6, as well as the anti-inflammatory cytokine IL-10. Stimulation in the presence of p-HBAD-I significantly suppressed the production of TNF-α and IL-12p40 in response to irradiated M. Tuberculosis H37RV, but had a reduced effect on IL-6 production and no effect on IL-10 production. Similarly, co-incubation of Bone-marrow derived macrophages (BMM) with UM-p-HBAD-I significantly reduced the production of TNF-α compared to cells stimulated with H37Rv alone, and also had no effect on IL-10 production induced by the irradiated bacteria. In contrast to the results obtained from the splenocyte studies, p-HBAD-II did not appear to affect proinflammatory cytokine production by BMM co-stimulated with irradiated H37Rv. This data shows that p-HBAD-I and UM-p-HBAD-I suppress TNF-α production but exert no effect on the production of the cytokines IL-10 or IL-6.
Conclusions
For the first time a number of synthetic p-HBADs have been prepared and their immunomodulatory effects have been studied in isolation from the parent bacterium. It has been determined that these small molecules have the ability to suppress host immune response in vitro but that they are not immunostimulatory in themselves. 
Compound 12
Trifluoromethanesulfonic anhydride (0.328 mL, 1.49 mmol) was added to a solution of dimethyl disulfide (0.195 mL, 2.3 mmol) in anhydrous DCM (1 mL) at 0°C and reacted for 30 min at 0°C to give a dark yellow solution. 11 (520 mg, 1.29 mmol) was dissolved in anhydrous DCM (7 mL) under N 2 at 0°C along with methyl 4-hydroxybenzoate (296 mg, 1.94 mmol). 
Compound 21
20 (118 mg, 0.129 mmol) was dissolved in THF and a catalytic amount of palladium on carbon added. The mixture was degassed under vacuum and then stirred vigorously under a hydrogen atmosphere until TLC analysis indicated the consumption of the starting material. A N 2 atmosphere was introduced before exposing the mixture to air. The palladium was filtered off and the resulting solution concentrated. Purification by column chromatography (40 : 60 acetone-toluene)
